NCT05170048View on ClinicalTrials.gov

Study to Evaluate Safety and Efficacy of EG-301 in Patients with Nonfocal Geographic Atrophy Secondary to DAMD

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Non-Exudative (dry) Age-related Macular Degeneration (dAMD)
Interventions
DRUG

EG-301

The investigation drug, EG-301 Tablets 150mg, is for oral use.

DIETARY_SUPPLEMENT

AREDS2 supplements

AREDS2 supplement is the stand of care

Sponsors
All Listed Sponsors
lead

Evergreen Therapeutics, Inc.

INDUSTRY